2022 was a year of transformation and change: reported $412.5 million in total revenue for the year ended December 31, 2022 ; reported net income of $124.3 million ( $1.90 per fully diluted share) for 2022 compared to net loss of $211.8 million in 2021; reported $492.2 million in cash resources as  Continue Reading

VANCOUVER, British Columbia --(BUSINESS WIRE)--Feb. 28, 2023-- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management will participate in the following upcoming investor conferences: Barclays Global  Continue Reading

VANCOUVER, British Columbia --(BUSINESS WIRE)--Feb. 21, 2023-- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management will report its fourth quarter and full year 2022 financial results after market  Continue Reading

VANCOUVER, British Columbia --(BUSINESS WIRE)--Jan. 25, 2023-- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management will participate in the following upcoming investor conferences: Guggenheim  Continue Reading

Results presented   today   at ASCO GI include first overall survival (OS) data for zanidatamab, overall confirmed objective response rate (cORR) of 79%, disease control rate (DCR) of 92%, and median progression-free survival (mPFS) of 12.5 months Ongoing Phase 3 randomized clinical trial,  Continue Reading

Provides updated key priorities and focus on enterprise value framework Closing of Jazz Pharmaceuticals (Jazz) collaboration in fourth quarter completes financial transformation initiatives originally planned for 2022 Announces additional financial guidance on expected cash runway; provides  Continue Reading